Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.08 Analyst target: $4.17 Upside: 100.34%
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.